Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability.

Détails

ID Serval
serval:BIB_AFB4A7406A45
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability.
Périodique
Therapeutic drug monitoring
Auteur⸱e⸱s
Marzolini C., Buclin T., Decosterd L.A., Biollaz J., Telenti A.
ISSN
0163-4356 (Print)
ISSN-L
0163-4356
Statut éditorial
Publié
Date de publication
08/2001
Peer-reviewed
Oui
Volume
23
Numéro
4
Pages
394-398
Langue
anglais
Notes
Publication types: Comparative Study ; Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
Nelfinavir has been recently approved as a twice-daily (BID) dose regimen, but no evaluation of the influence of this regimen change on patients' protease inhibitor exposure has been published. The aim of this study was to compare trough plasma concentrations of nelfinavir obtained under the 1250-mg b.i.d regimen with the levels achieved with the original 750-mg three-times-daily (TID) regimen in 56 HIV-infected patients. Blood samples were obtained at steady state before the morning dose of nelfinavir. Plasma levels were measured by high-performance liquid chromatography. Eleven and 45 patients were following TID and BID regimens, respectively. Trough concentrations ranged from 0.14 to 11.74 mg/L and from 0.36 to 10.57 mg/L under TID and BID regimens, respectively. Large interpatient (coefficient of variation: 153%) and modest intrapatient (45%) variabilities of nelfinavir levels were observed. Twenty-one patients (38%) and six patients (11%) had levels above and below, respectively, the trough nelfinavir range (1.0--3.0 mg/L) recommended by the manufacturer. Trough levels are not affected by the dosing regimen; they mainly reflect the important interindividual variability, while remaining fairly stable over time. Many subjects had plasma levels repeatedly outside the assumed therapeutic range. Dose adjustment based on therapeutic drug monitoring may contribute to optimizing antiretroviral therapy.
Mots-clé
Adult, Chromatography, High Pressure Liquid, Drug Administration Schedule, Drug Monitoring, Female, HIV Infections/drug therapy, HIV Infections/metabolism, HIV Protease Inhibitors/administration & dosage, HIV Protease Inhibitors/pharmacokinetics, Humans, Male, Nelfinavir/administration & dosage, Nelfinavir/pharmacokinetics
Pubmed
Web of science
Création de la notice
25/01/2008 10:41
Dernière modification de la notice
06/08/2024 6:02
Données d'usage